Open AccessThe role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer
Author(s) -
Yuki Katayama,
Tadaaki Yamada,
Takayuki Shimamoto,
Masahiro Iwasaku,
Yoshiko Kaneko,
Junichi Uchino,
K. Takayama
Publication year - 2019
Publication title -
translational lung cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 41
eISSN - 2226-4477
pISSN - 2218-6751
DOI - 10.21037/tlcr.2019.10.23
Subject(s) - medicine , microbiome , immunotherapy , lung cancer , biomarker , immune system , pembrolizumab , cancer , gut flora , oncology , immunology , bioinformatics , biology , biochemistry
Cancer immunotherapy is being developed as a promising alternative for advanced non-small cell lung cancer (NSCLC). However, novel biomarkers are required to select patients that will benefit from treatment with immune checkpoint inhibitors (ICIs) for a long period of time. The gut microbiome is expected to be a promising biomarker of ICI response owing to the regulation of the immune status within the host.